New nucleoside analogs for patients with hematological malignancies. - Wikidata - awgldk - TriplyDB

New nucleoside analogs for patients with hematological malignancies.

New nucleoside analogs for patients with hematological malignancies.

http://www.wikidata.org/entity/Q37841589

about

Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides Nucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNA-methyltransferase inhibitors.Low expression of T-cell transcription factor BCL11b predicts inferior survival in adult standard risk T-cell acute lymphoblastic leukemia patients Artesunate-enhanced apoptosis of human high-risk myelodysplastic cells induced by the DNA methyltransferase inhibitor decitabine.Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine.French "real life" experience of clofarabine in children with refractory or relapsed acute lymphoblastic leukaemia.Translocation of nucleoside analogs across the plasma membrane in hematologic malignancies.Epigenetic-based therapies in cancer: progress to date.DNA methylation and cancer diagnosis.Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers.Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine.Therapeutic targets for altering mitochondrial dysfunction associated with diabetic retinopathy.Targeting DNA Methyltranferases in Urological Tumors.

P2860

Q28485227-C2DBADE0-3F88-483F-8131-BD2D0ECCA054 Q34025097-1E733C99-CD61-4513-B96F-A421890CD320 Q34469099-74774740-0611-4906-B02A-D9FA59570984 Q35681469-61F8479B-C971-4826-B950-A991A3D20137 Q35870211-D54593FC-A377-4FE6-A09D-D32A79F901DF Q36689775-C34CA573-FD61-4BE7-AF14-09A95E4C73C7 Q37963498-6E1E7DA1-C5D5-4242-9B7F-C2CADEBC2684 Q37964702-6C8C7112-19E7-44A2-BFD8-D793BBFDC3A3 Q38123094-3CCEDAF8-A9E8-43DE-8F3A-DA119E20330C Q39363811-E3455719-6232-4B75-A687-5DB10E4822B7 Q48655141-1FABB616-FAC1-4768-AFB6-0A743A255297 Q50049076-BB802F41-B8D3-4858-8D45-2B4B5A3E3869 Q55435258-86047F63-C55A-4AB0-983B-285902946162

P2860

New nucleoside analogs for patients with hematological malignancies.

http://www.wikidata.org/entity/Q37841589

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

New nucleoside analogs for patients with hematological malignancies.

@en

New nucleoside analogs for patients with hematological malignancies.

@nl

type

label

New nucleoside analogs for patients with hematological malignancies.

@en

New nucleoside analogs for patients with hematological malignancies.

@nl

prefLabel

New nucleoside analogs for patients with hematological malignancies.

@en

New nucleoside analogs for patients with hematological malignancies.

@nl

P1433

Q37841589-DEA0FA8B-3ACA-4035-B8F9-79AE073CC21F

P1476

Q37841589-3916CCF7-990D-438E-BFC8-68B85A5596DE

P2093

Q37841589-8490C8E9-895D-44D3-9329-5D20B58E1C44

P2860

Q37841589-01F776C6-96FF-4124-BE05-F245C97B1ED4

Q37841589-04BC06CA-8F71-4B1F-B3FB-7E1E117CB6FA

Q37841589-0B0DFDEA-BF70-477F-8354-C1BC7C6E3243

Q37841589-0F7B95A4-BD0F-42E2-AEE6-0C0C2D98F7C6

Q37841589-11ED4591-D095-4F9F-BE02-8AC13357969D

Q37841589-126665C0-3BEA-45FA-9D67-1D3EE4DBAAAA

Q37841589-1EB7A99E-4A0D-4CAF-A064-E8259925F7AE

Q37841589-20739BAE-FA3D-44B9-B2B8-E468CBA62857

Q37841589-23A5AA52-4175-40D7-8A20-FCA630002496

Q37841589-23BAA9F9-3D39-4087-BE9B-35BA43F00B32

P304

Q37841589-B3DB62D9-6086-4DAA-AA9C-599DE83D6F81

P31

Q37841589-D56B234A-C0F5-45DC-A01F-92371BD1FAB8

P356

Q37841589-D601C665-64CB-4254-9E10-DCB5531A69A3

P407

Q37841589-A12C12E9-EEAA-4440-91EE-B79D4DCE6476

P433

Q37841589-F37A3874-0BC0-49EC-880F-ECB569FC368E

P478

Q37841589-F62F811B-001E-429C-AEF0-F114EB66A1B9

P577

Q37841589-72ED19D6-2AEE-4B2D-A011-563C29B951B4

P698

Q37841589-A53DFDDA-BFF4-4B4C-9856-EE18A2FDA588

P921

Q37841589-65FD9856-9153-4F8A-AD50-460D27ABD7FA

P356

13543784.2011.554822

P1433

Expert Opinion on Investigational Drugs

P1476

New nucleoside analogs for patients with hematological malignancies.

@en

P2093

Tadeusz Robak

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer

Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells

Zebularine: A Novel DNA Methylation Inhibitor that Forms a Covalent Complex with DNA Methyltransferases

A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines

Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.

Ataxia-telangiectasia and Rad3-related and DNA-dependent protein kinase cooperate in G2 checkpoint activation by the DNA strand-breaking nucleoside analogue 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine.

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.

Phase I trial of nelarabine in indolent leukemias.

Forodesine: review of preclinical and clinical data.

P304

343-359

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2011.554822

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21320002

http://www.w3.org/2001/XMLSchema#string

P921